.png "NxStage Medical (NASDAQ: NXTM)")
Today, a Director at NxStage Medical, Daniel Giannini , exercised options of NxStage Medical (NASDAQ: NXTM) for $247.5K. The options were close to expired and Daniel Giannini retained stocks.
This recent transaction increases Daniel Giannini’s holding in the company by 28.79% to a total of $2.13 million. Following Daniel Giannini’s last NXTM Buy transaction on November 22, 2016, the stock climbed by 1.7%.
See today’s analyst top recommended stocks >>
Based on NxStage Medical’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $107 million and GAAP net loss of $1.46 million. In comparison, last year the company earned revenue of $96.83 million and had a GAAP net loss of $1.19 million. Currently, NxStage Medical has an average volume of 99.72K. The Company has a Price to Book ratio of 7.8685.
Nine different firms, including BTIG and Canaccord Genuity, currently also have a Buy rating on the stock. Based on 3 analyst ratings, the analyst consensus is Hold with an average price target of $30.00, reflecting a -12.4% downside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NxStage Medical, Inc. is a medical technology company, which develops, manufactures, and markets products for the treatment of ESRD and acute kidney failure. It operates through the following business segments: System One, In-Center, and Services.
